Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis.

European journal of clinical pharmacology - 1 Jan 1997

Christensen P M, Gøtzsche P C, Brøsen K

Abstract excerpt

OBJECTIVE: To examine the association between the sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer. METHOD: Meta-analysis of case-control studies using a random effects model. The "Main outcome measure" was the odds ratio for the risk of lung cancer, using extensive metabolisers as the reference group. RESULTS: Thirteen studies were identified. The studies were too heterogeneous...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease Susceptibility
Share to Genotype
Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Odds Ratio

Share to Oxidation-Reduction

Share to Phenotype

Share to Polymorphism, Genetic

Share to Risk Factors

Source

Identifiers

PMID: 9049580
DOI: 10.1007/s002280050219

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis.PMID 9049580Read ↗

Debrisoquin oxidation genotype and susceptibility to lung cancer.Semantic proximity Read ↗

Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphism.Semantic proximity Read ↗

Human CYP2D6 gene polymorphism in Slovene cancer patients and healthy controls.Semantic proximity Read ↗

Polymorphism in CYP1A1 and CYP2D6 genes: possible association with susceptibility to lung cancer.Semantic proximity Read ↗

Is there a link between debrisoquine oxidation phenotype and lung cancer susceptibility?Semantic proximity Read ↗

Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.Semantic proximity Read ↗

Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer.Semantic proximity Read ↗

DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolisers.Semantic proximity Read ↗

Debrisoquine metabolism and lung cancer risk.Semantic proximity Read ↗

CYP1A1 and CYP2D6 polymorphism and risk of lung cancer in a North Indian population.Semantic proximity Read ↗

Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls.Semantic proximity Read ↗

Debrisoquine oxidation phenotype and susceptibility to lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.